Vergelijking
Mazdutide vs. Semaglutid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2259884-03-0
910463-68-2
Molecuulmassa
4790 g/mol
4113.6 g/mol
Halfwaardetijd
132 h
165 h
Sequentie
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkettemodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerWerkingsmechanisme
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
4
waarvan bij mensen
4
3
Geregistreerde effecten
4
3
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
0
5
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Mazdutide and Semaglutid?
- Mazdutide is classified as "Metabool", while Semaglutid is classified as "Metabool". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Semaglutid?
- The highest available evidence level is "Humane RCT" for Mazdutide and "Humane RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Semaglutid in Germany and the United States?
- Duitsland: Mazdutide — Alleen onderzoek, Semaglutid — Op recept. Verenigde Staten: Mazdutide — Alleen onderzoek, Semaglutid — Op recept. These are factual summaries with source and review date on the individual pages.